Search company, investor...

Carigent Therapeutics

carigent.com

Founded Year

2007

About Carigent Therapeutics

Carigent Therapeutics is a biotechnology firm located in New Haven, CT dedicated to the development of next-generation therapeutic agents using a proprietary platform that is extremely versatile and robust.

Headquarters Location

5 Science Park Suite 13

New Haven, Connecticut, 06520,

United States

Missing: Carigent Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Carigent Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Carigent Therapeutics Frequently Asked Questions (FAQ)

  • When was Carigent Therapeutics founded?

    Carigent Therapeutics was founded in 2007.

  • Where is Carigent Therapeutics's headquarters?

    Carigent Therapeutics's headquarters is located at 5 Science Park, New Haven.

  • Who are Carigent Therapeutics's competitors?

    Competitors of Carigent Therapeutics include Seattle Genetics, Cell Point, Pique Therapeutics, Decimmune Therapeutics, Immutep and 12 more.

Compare Carigent Therapeutics to Competitors

Fyodor Biotechnologies Logo
Fyodor Biotechnologies

Fyodor is a Baltimore company working with Johns Hopkins University to develop malaria tests.

V
Viridaxis

Viridaxis is a biotechnology firm working for integrated pest management.

A
ASD Biosystems

ASD BioSystems, Inc. is working to be the market leader in providing total, integrated, ultra-portable, rugged, decontaminable, rapid systems for sample collection, tracking, analysis,  reporting and management for a rapidly expanding biosafety market. The biosafety market includes biotechnology and manufacturing control testing, agricultural and veterinary testing, environmental testing, and responding to known or suspected acts of biological warfare, bioterrorism or other related criminal activity.

S
Spaltudaq

Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

P
Pique Therapeutics

Pique Therapeutics is a biotechnology company focused initially on the treatment of cancer. Pique's lead product is a therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing its therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.